Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 USD | -3.21% | -10.59% | +19.89% |
Mar. 14 | Top Premarket Gainers | MT |
Mar. 13 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 46.7 | 12.18 | 14.79 | 18.02 | - | - |
Enterprise Value (EV) 1 | 46.7 | 12.18 | 14.79 | 18.02 | 18.02 | 18.02 |
P/E ratio | -3.02 x | -0.84 x | -0.96 x | -1.06 x | -1.48 x | -1.66 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 8,194 | 8,401 | 8,401 | 8,539 | - | - |
Reference price 2 | 5.700 | 1.450 | 1.760 | 2.110 | 2.110 | 2.110 |
Announcement Date | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -7.729 | -14.91 | -16.38 | -21.4 | -24.4 | -23.63 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -7.711 | -14.32 | -15.42 | -21.1 | -24.1 | -23.63 |
Net income 1 | -3.584 | -7.711 | -14.32 | -15.42 | -21.1 | -24.1 | -23.63 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -4.890 | -1.890 | -1.730 | -1.830 | -1.995 | -1.425 | -1.270 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/20/21 | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -3.368 | -3.218 | -3.402 | -3.869 | -3.553 | -4.087 | -4.455 | -3.495 | -4.248 | -4.18 | -4.9 | -5.1 | -5.3 | -5.5 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.367 | -3.216 | -3.365 | -3.836 | -3.466 | -3.656 | -4.253 | -3.245 | -3.922 | -4.003 | -4.83 | -5.05 | -5.03 | -5.29 |
Net income 1 | -3.367 | -3.216 | -3.365 | -3.836 | -3.466 | -3.656 | -4.253 | -3.245 | -3.922 | -4.003 | -4.83 | -5.05 | -5.03 | -5.29 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.8100 | -0.2200 | -0.4100 | -0.4600 | -0.4200 | -0.4400 | -0.5100 | -0.3900 | -0.4700 | -0.4700 | -0.5700 | -0.6000 | -0.4200 | -0.3400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/21/22 | 5/12/22 | 8/8/22 | 11/10/22 | 3/17/23 | 5/11/23 | 8/14/23 | 11/6/23 | 3/13/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 4/20/21 | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.89% | 18.02M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INDP Stock
- Financials Indaptus Therapeutics, Inc.